BillionToOne (BLLN) CEO Oguzhan Atay Sells $574K of Stock
Chairman and CEO Oguzhan Atay sold 5,850 shares of BillionToOne, Inc. stock on October 14, 2026, for approximately $574,385.
Reviewed by automated data checks against the source filing. How we make and check alerts
Oguzhan Atay, Chairman and CEO at BillionToOne, Inc. ($BLLN), sold 5,850 shares at an average price of $98.19, worth about $574,385.76, on October 14, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $BLLN is up 0.2% to date (from the $97.88 close on Oct 14, 2026).
BLLN
BillionToOne, Inc.
Key Points
- Chairman and CEO Oguzhan Atay sold 5,850 shares of BillionToOne, Inc. (NasdaqGS: BLLN) on October 14, 2026, at an average price of $98.19 per share.
- The transaction was filed via a Form 4 with the SEC and was executed under a pre-arranged Rule 10b5-1 trading plan.
- BillionToOne trades in the healthcare diagnostics space with trailing twelve month revenue of $397.4 million and positive net income.
Get $BLLN trade alerts by text
We text you when insiders, Congress or big funds trade $BLLN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BillionToOne, Inc. alert may contain errors. Disclosures
BillionToOne, Inc. Chairman and CEO Oguzhan Atay sold 5,850 shares of the company's stock on October 14, 2026. According to a Form 4 filed with the SEC, the shares were sold at an average price of $98.19, for a total transaction value of $574,385.76. The sale was executed pursuant to a pre-arranged trading plan. Shares of BillionToOne closed at $97.88 on the day of the trade.
Inside Oguzhan Atay's BillionToOne Trade
The transaction involved 5,850 shares held directly by Atay, leaving him with a smaller direct stake in the diagnostics firm. The trade was made under a pre-arranged Rule 10b5-1 plan, which lets company insiders set up stock trades ahead of time to avoid concerns about trading on inside information. Atay previously executed other planned sales of company stock earlier in October.
Other Institutional Activity in BillionToOne, Inc.
Other major funds adjusted their holdings in BillionToOne recently. Adams Street Partners, LLC held steady with 1,711,430 shares worth about $167,925,516. Baillie Gifford & Co reduced its stake by 358,602 shares, ending with 901,420 shares valued at about $88,447,332. Neuberger Berman Group, LLC added 55,033 shares to hold 764,215 shares worth roughly $74,984,777. BAMCO Inc. increased its holdings by 593 shares to finish with 742,093 shares worth about $72,814,167. Wasatch Advisors LP trimmed its position by 10,828 shares, leaving it with 507,258 shares valued at about $49,772,156.
BillionToOne, Inc. Stock Down 5.0%
BillionToOne shares recently traded around $97.58 as of October 16, 2026, down about 0.3% from the event close. The stock sits below its 50-day moving average of $100.75 but above its 200-day moving average of $95.49.
Recent Earnings
BillionToOne reported trailing twelve month revenue of $397,412,000 with a net profit margin of 8.3%. The company posted basic earnings per share of $0.63 over the same period, alongside a return on equity of 10.7%. The next corporate earnings update is scheduled for November 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 0 raises.
-
EPS & revenue
EPS beat estimates by 598.2%. Revenue beat estimates by 9.7%.
-
Profit surprise
EBITDA beat sharply. Operating income beat sharply.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target cuts.
-
Earnings quality
Gross margin up 8.6 points. Operating margin up 20.4 points.
Earnings Call Summary
BillionToOne delivered a standout quarter with 108.4 million dollars in revenue, up 84 percent year over year, while achieving 16 percent operating profit margin and 24 percent adjusted EBITDA margin. Prenatal revenue hit 97.7 million dollars, up 72 percent, and oncology revenue nearly quintupled to 10.7 million dollars. The company launched Unity Confirm, a first noninvasive fetal cell confirmation test, and signed landmark payer contracts with Anthem and United, now covering 300 million lives. Gross margins expanded to 73 percent, up 9 percentage points year over year, driven by higher pricing per test and lower production costs despite growing oncology volume.
Guidance Management raised 2026 total revenue guidance to 445 to 465 million dollars, up 20 million dollars from prior March guidance. They expect 48 to 52 percent growth versus 2025 results. The raise reflects strong Q1 performance and new payer contracts expected to boost pricing per test over the rest of the year.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Insider Buying and Selling at BillionToOne, Inc.
Several other insiders traded company shares prior to Atay's sale. John Roderick Ten Bosch sold 2,834 shares on October 5, 2026, for about $297,995. Chief Technology Officer David Tsao sold 20,000 shares on October 5, 2026, valued at approximately $2,162,950. Atay also executed earlier sales, including 19,334 shares sold on October 12, 2026, for about $1,823,449.
Analysts Set New Price Targets
Wall Street firms maintain an active coverage slate for the company. Guggenheim maintained a buy rating with a $128 price target on October 1, 2026, following earlier target adjustments from JP Morgan, BTIG, and Canaccord Genuity. The stock carries a consensus recommendation of strong buy.
About BillionToOne, Inc.
BillionToOne, Inc. operates as a precision diagnostics company based in Menlo Park, California. The firm builds molecular counting platforms designed to measure DNA molecules at a single-count level, helping clinicians enhance disease detection and reproductive health screening.
Bottom Line
Insiders continue to manage their personal equity holdings via scheduled transactions as the company heads toward its next financial report on November 4, 2026. Investors can review future Form 4 filings for further updates on executive transactions.
Related Filing Alerts
Source: Oguzhan Atay's Form 4 filing on $BLLN (Oct 14, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts